<table>
<thead>
<tr>
<th><strong>Title</strong></th>
<th>E-cadherin in gastric cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Author(s)</strong></td>
<td>Chan, AOO</td>
</tr>
<tr>
<td><strong>Citation</strong></td>
<td>World Journal of Gastroenterology, 2006, v. 12 n. 2, p. 199-203</td>
</tr>
<tr>
<td><strong>Issued Date</strong></td>
<td>2006</td>
</tr>
<tr>
<td><strong>URL</strong></td>
<td><a href="http://hdl.handle.net/10722/194550">http://hdl.handle.net/10722/194550</a></td>
</tr>
<tr>
<td><strong>Rights</strong></td>
<td>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</td>
</tr>
</tbody>
</table>
E-cadherin in gastric cancer

Annie On On Chan

INTRODUCTION

Although decreasing in incidence, gastric cancer remains a major medical problem and is the second most common fatal cancer worldwide. In spite of intense interest and extensive investigations, its prognosis has not been improved significantly in recent years. The dramatic variations in the incidence of gastric cancer in different geographic areas and from one generation to the next have led to the hypothesis that the incidence of gastric cancer is determined largely by environmental rather than genetic factors. The identification and the subsequent classification of *Helicobacter pylori* (H pylori) infection as type I carcinogen by the WHO sparked a significant understanding in the etiology of gastric cancer. The current discovery of germline mutation at E-cadherin gene in familial gastric cancers and the findings of IL-1 polymorphisms with increased gastric cancer risk again turn the focus towards the studying of host genetics. The molecular studies of the host may give a definite proof of the etiologic role of *H pylori* in inducing gastric carcinoma.

Only a small fraction of all cancers arise in individuals who carry a germline defect conferring genetic predisposition. Nevertheless, many genes that underlie inherited cancer syndromes have more widespread roles in sporadic cancers, as a result of somatic mutations that arise during tumor initiation or progression. Hence, in this review paper, we shall focus on the E-cadherin gene, one of the candidate genes in gastric cancer, and the work we have done on E-cadherin in gastric carcinogenesis.

E-CADHERIN

Cadherins are a superfamily of calcium-mediated membrane glycoproteins. E-cadherin is the prototype of the class E-cadherin that links to catenins to form the cytoskeleton. Recent evidence has shown that E-cadherin not only acts as an adhesive, but also plays important roles in growth development and carcinogenesis. It has been recently viewed as an invasion as well as a growth suppressor gene. This review summarizes the recent discoveries on E-cadherin and its role in gastric cancer. In particular, our work on E-cadherin in gastric cancer, including its relation with *Helicobacter pylori* and clinical applications, are described in detail.

E-CADHERIN AND CANCER

Role of E-cadherin in metastasis

E-cadherin is the prototype of the cadherin class. It is expressed in all epithelial cell types. Underexpression of the E-cadherin is found in gastric and other cancers, and correlates with infiltrative and metastatic ability. It has been proposed that the loss of E-cadherin-mediated cell-cell adhesion is a prerequisite for tumor cell invasion and metastasis formation. Re-establishing the functional cadherin complex, e.g. by forced expression of E-cadherin, results in a reversion from an invasive, mesenchymal, to a benign, epithelial phenotype of cultured tumor cells. Hence, the E-cadherin gene is also called as an invasion

Abstract

Cadherin is an adhesion molecule and a superfamily of calcium-mediated membrane glycoproteins. E-cadherin is the prototype of the class E-cadherin that links to catenins to form the cytoskeleton. Recent evidence has shown that E-cadherin not only acts as an adhesive, but also plays important roles in growth development and carcinogenesis. It has been recently viewed as an invasion as well as a growth suppressor gene. This review summarizes the recent discoveries on E-cadherin and its role in gastric cancer. In particular, our work on E-cadherin in gastric cancer, including its relation with *Helicobacter pylori* and clinical applications, are described in detail.

© 2006 The WJG Press. All rights reserved.

Key words: E-cadherin; Gastric cancer


http://www.wjgnet.com/1007-9327/12/199.asp
suppressor gene.

Role of E-cadherin in oncogenesis

Recently, it has been postulated that the role of E-cadherin in carcinogenesis does not limit only to metastasis and invasion (Figure 1). It is now being increasingly recognized that there is also a possible role of E-cadherin in modulating intracellular signaling, and thus promoting tumor growth. There are several lines of evidence. Cadherin-mediated cell-cell adhesion can affect the Wnt-signaling pathway. β-catenin (as well as γ-catenin) is usually sequestered by cadherins in the cadherin-catenin complex. Upon loss of E-cadherin function, non-sequestered, free β-catenin is usually phosphorylated by glycogen synthase kinase 3β (GSK-3β) in the adenomatous polyposis coli (APC)-axin-GSK-3β complex and subsequently degraded by the ubiquitin-proteasome pathway. In many cancer cells, loss of function of the tumor suppressor APC, mutations in β-catenin or inhibition of GSK-3β by the activated Wnt-signaling pathway leads to the stabilization of β-catenin in the cytoplasm. Subsequently, it translocates to the nucleus, where it binds to the members of the Tcf/Lef-1 family of transcription factors and modulates expression of Tcf/Lef-1-target genes, including the proto-oncogene c-myc and cyclin D1. In addition, recent studies on familial gastric cancer indicate that E-cadherin can also act at a much earlier stage during tumor development. Mutations of the E-cadherin gene were found in three familial gastric cancer kindreds from New Zealand\[13\] and this observation was confirmed in the kindred of European origin\[18\]. These results demonstrate that loss of function of E-cadherin may play a role in susceptibility to initial tumor development in addition to its role as an inhibitor of tumor invasion.

EXPRESSION OF E-CADHERIN IN GASTRIC CANCER

The expression of E-cadherin has been studied by immunohistochemical method. Decreased expression has been observed in gastric cancer by various authors, ranging from 17%\[13\] to 92%\[14\], depending on the method and the definition used. The decreased expression of E-cadherin was mainly observed in diffuse type and less in intestinal type of gastric cancer. Direct correlation between E-cadherin and the grade of tumor differentiation has been observed in all these studies. In addition, it was shown in a study of 413 gastric cancers by Gabbert et al.\[15\] that patients with E-cadherin positive tumors had significantly better 3- and 5-year survival rates than patients with E-cadherin negative tumors. A similar trend of decrease in disease-free survival was also observed in other cancers exhibiting downregulation of E-cadherin\[16\].

We have also studied the change in the expression of the E-cadherin complex along the Correa's cascade in gastric cancer by immunohistochemical staining\[17\]. We observed that the staining pattern, intensity and the percentage of cells with positive stains deceased along the Correa's cascade; that is, the staining was strong and membranous in normal gastric epithelium, but gradually decreased in intensity and percentage, as well as the pattern was changed towards cytoplasm in chronic atrophic gastritis, intestinal metaplasia, dysplasia and eventually to adenocarcinoma.

However, methods to evaluate, qualitatively or quantitatively, protein expression in biopsies from human tumors may have serious limitations because of sampling from heterogeneous tissue, non-stoichiometric labeling and subjective evaluation.

MECHANISM OF INACTIVATION OF E-CADHERIN

Genetic inactivation

The E-cadherin gene can be genetically inactivated by a number of mechanisms. The first hit of a role for E-cadherin in tumor development, particularly in suppression of invasion, came from loss of heterozygosity studies on chromosome 16. Subsequently, mutations were reported in tumor samples in diffuse type gastric carcinomas\[18\], gynecologic cancers\[19\], and infiltrative lobular breast cancer\[20,21\]. In gastric cancer, E-cadherin mutations are common in

www.wjgnet.com
Infection was associated with increased methylation. Methylation was detected in 46% (19/41) after eradication treatment. Methylation was assessed using methylation assay at week 0 (before treatment) and week 6 (after treatment). Methylation frequency correlated with the tumor depth and node invasion. In addition, most of the lesions detected in the tumorous lesions and metastatic lesions were sequenced that by eradicating H. pylori, the role of E-cadherin has been studied recently. It has been shown that E-cadherin has a cleavage site near the transmembrane domain, and the resulting increase in permeability mediated by calcium-dependent proteolytic action, and can be detected in the disassembly of the cytoplasmic adhesion complex and cell disassembly. E-cadherin has been shown to be increased in dermatological disorders (bullous pemphigoid, pemphigus vulgaris, pemphigus foliaceus), and can be detected in the protein extract of tissue samples from peripheral blood and urine in normal subjects. The role of soluble E-cadherin and its cleavage site in the transmembrane domain and artificially produces a soluble 80 kDa fragment in the culture medium upon trypsin digestion in the presence of calcium. This soluble E-cadherin fragment is considered to be a degradation product of the 120 kDa intact E-cadherin generated by a calcium-dependent proteolytic action, and can be detected in the protein extract of tissue samples from peripheral blood and urine in normal subjects. Serum soluble E-cadherin is reported to be increased in dermatological disorders (bullous pemphigoid, pemphigus vulgaris, pemphigus foliaceus), multi-organ failure, and various tumors like bladder cancer, prostate cancer, lung cancer and gastric cancer. The role of soluble E-cadherin and its biological significance is still at present, unclear. Recent studies indicate that, in inflammatory condition, serum E-cadherin in gastric cancer

Inactivation by hypermethylation

In recent years, it has become increasingly apparent that increased methylation within the promoter regions of genes plays a key role in the inactivation of many important genes during the development of cancer. Subsequently, numerous reports of E-cadherin promoter methylation, associated with reduced E-cadherin expression, have been published. Hypermethylation at E-cadherin has also been shown to play a role in familial gastric cancer, acting as the second hit (the first hit is either mutation or loss of heterozygosity) in inactivation of E-cadherin.

We have previously shown that the immunostaining of E-cadherin decreases along the Correa’s cascade; therefore, we went on to study the underlying mechanism. We found that the frequency of methylation at E-cadherin also increases along the Correa’s cascade, with the highest frequency detected in the tumorous lesions and metastatic lesions. The methylation frequency correlated with the tumor depth and node invasion. In addition, most of the decrease in immunostaining was accounted for by the presence of methylation at E-cadherin. More importantly, we also observed that H. pylori infection was also associated with E-cadherin methylation.

In fact, the role of H. pylori in the regulation of E-cadherin has been studied recently. It has been shown that H. pylori infection is associated with downregulation of E-cadherin, probably by generating cell signaling events that counteract the normal function of protein kinase C. The resulting increase in permeability mediated by the reduction in cell adhesion might allow H. pylori antigens to reach the gastric lamina propria and activate the mucosal immune system, with resultant tissue damage.

In relation to the above findings, we therefore hypothesized that by eradicating H. pylori, methylation at E-cadherin may disappear. We performed a prospective randomized trial. Patients with dyspepsia and H. pylori infection were randomized to receive H. pylori eradication therapy (Group 1, n=41) or no treatment (Group 2, n=40) and were followed up prospectively. Gastric mucosae were taken for methylation assay at week 0 (before treatment) and week 6 (after treatment). Methylation was assessed using methylation-specific PCR. Methylation was detected in 46% (19/41) and 17% (7/41) at week 0 and 6, respectively in Group 1 (P=0.004). 78.9% (15/19) specimens turned unmethylated after eradicating H. pylori. Methylation was detected in 47.5% (19/40) and 52.5% (21/40) at weeks 0 and 6, respectively in Group 2 (P=0.5). Archived specimens with intestinal metaplasia with H. pylori infection (n=22) and without the infection (n=19) were also retrieved for methylation analysis. But methylation frequency did not differ in H. pylori positive or negative intestinal metaplastic specimens (72.7% vs. 63%, P=0.5). Therefore, we postulated that H. pylori eradication therapy could reverse methylation in patients with chronic gastritis only and may halt the process of gastric carcinogenesis.

Postulated mechanism of helicobacter pylori infection for inducing methylation

Experimental data from in vitro studies support our contention that E-cadherin methylation might be related to H. pylori infection. El-Omar et al. reported that interleukin-1β polymorphism that led to upregulation of interleukin-1β with H. pylori infection was associated with increased risk of gastric cancer. Furthermore, Hmadcha et al. found that interleukin-1β, through the production of nitric oxide and the subsequent activation of DNA methyltransferase, might induce gene methylation. It is thus possible that H. pylori induces methylation through the production of interleukin-1β and hence the downstream activation of nitric oxide and DNA methyltransferase, which subsequently led to an increased risk of E-cadherin methylation and hence gastric cancer.

OTHER REGULATORY MECHANISMS OF E-CADHERIN

Loss of E-cadherin function during tumor progression can also be caused by transcriptional repression binding to the CDH1-E box elements, e.g. by the repressors Snaïl and Sip-1. Tyrosine phosphorylation has also been previously implicated in the regulation of cadherin function: RTKs, such as EGFR, c-Met and FGFR, and the non-receptor tyrosine kinase, c-Src, phosphorylate E-cadherin, N-cadherin, β-catenin, -catenin and p120ctn, resulting in the disassembly of the cytoplasmic adhesion complex and a disruption of cadherin-mediated cell adhesion and cell scattering.

SOLUBLE E-CADHERIN

E-cadherin has a cleavage site near the transmembrane domain and artificially produces a soluble 80 kDa amino-terminal fragment in the culture medium upon trypsin digestion in the presence of calcium. This soluble E-cadherin fragment is considered to be a degradation product of the 120 kDa intact E-cadherin generated by a calcium-dependent proteolytic action, and can be detected in the protein extract of tissue samples from peripheral blood and urine in normal subjects. Serum soluble E-cadherin is reported to be increased in dermatological disorders (bullous pemphigoid, pemphigus vulgaris, psoriasis vulgaris), multi-organ failure, and various tumors like bladder cancer, prostate cancer, lung cancer and gastric cancer. The role of soluble E-cadherin and its biological significance is still at present, unclear. Recent studies indicate that, in inflammatory condition, serum
soluble E-cadherin is induced by inflammatory mediators and cytokines\(^9\); whereas in cancerous diseases, soluble E-cadherin is increased by cleavage of tissue E-cadherin due to overexpressed proteases\(^{10}\). The potential of soluble E-cadherin to be a prognostic marker in cancerous diseases has been shown in bladder cancer\(^{11}\) and gastric cancer\(^{12}\).

We have examined the potential clinical application of E-cadherin. We first studied the correlation between E-cadherin immunostaining expression and the concentration in sera\(^{13}\). We found that normal strong membranous staining, e.g. in normal gastric epithelium, was associated with low levels of serum soluble E-cadherin, but a partially reduced; cytoplasmic staining, e.g. in intestinal type of gastric cancer, was associated with high levels; whereas complete absence of staining, e.g. in diffuse type of gastric cancer, was associated with low levels of soluble E-cadherin. We also found that soluble E-cadherin may be a potentially useful prognostic marker. High levels of soluble E-cadherin correlated with the depth of tumor invasion, as well as inoperability\(^{14}\). More importantly, levels higher than 10 000 ng/mL predicts survival less than 3 years in more than 90% of patients\(^{15}\). Currently, we are investigating the use of post-operative soluble E-cadherin levels to predict tumor recurrence in patients who have received curative surgery for gastric cancer.

**CONCLUSION**

Being an adhesion molecule, E-cadherin plays an important role in invasion and metastasis in almost all kinds of epithelial malignancies, and hence is named invasion suppressor gene. However, recent studies have shown that E-cadherin actually plays an early and important role in carcinogenesis and acts as a tumor suppressor gene, particularly in gastric cancer. Further thorough understanding of the role of E-cadherin and its association with extracellular environment and intracellular functions will be extremely important. Potentially, reversing methylation at E-cadherin in the gastric epithelium in patients with *H pylori* infection may halt the process of future development of gastric cancer. In addition, soluble E-cadherin may be a useful prognostic marker for gastric cancer.

**REFERENCES**

Identification and purification of a cell surface glycoprotein mediating intercellular adhesion in embryonic and adult tissue. Cell 1983; 34: 455-466


Perry I, Tselepis C, Hoyland J, Iqbal TH, Scott D, Sanders SA, Cooper BT, Jankowski JA. Reduced cadherin/catenin complex expression in celiac disease can be reproduced in vitro by cytokine stimulation. Lab Invest 1999; 79: 1489-1499


S- Editor Guo SY  L- Editor Elsevier HK  E- Editor Li HY